LYTIR

Insider · SEC Form 4 · 10% Owner

Lynx1 Capital Management LP

In the 12 months to Nov 19, 2026, on the open market: bought $1.2M of KRRO, PASG. Filed a median of 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $1.2M in total; Insider sales: $0 in total.Jun: Insider purchases $206KAug: Insider purchases $79KOct: Insider purchases $885KDecJanFebMarAprMayJunJulAugSepOctNov$885K
Insider purchases above the line: $1.2MInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. KRROBought: Korro Bio, Inc. Oct 26, 2026 25,124 shares filed Oct 26, 2026 1,624,789 shares held indirectly after, as filed filing $295K
  2. KRROBought: Korro Bio, Inc. Oct 23, 2026 2,510 shares filed Oct 26, 2026 1,599,665 shares held indirectly after, as filed filing $30K
  3. KRROBought: Korro Bio, Inc. Oct 22, 2026 52,175 shares filed Oct 26, 2026 2 transactions filing $559K
  4. KRROBought: Korro Bio, Inc. Aug 10, 2026 1,462 shares filed Aug 13, 2026 1,544,980 shares held indirectly after, as filed filing $19K
  5. KRROBought: Korro Bio, Inc. Aug 6, 2026 5,222 shares filed Aug 13, 2026 1,543,518 shares held indirectly after, as filed filing $60K
  6. PASGBought: Passage BIO, Inc. Jun 25, 2026 50,055 shares filed Jun 29, 2026 673,759 shares held indirectly after, as filed filing $206K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. GHRSLynx1 Capital Management LP filed Aug 14, 2026 Schedule 13G/A passive issuer: GH Research PLC filing 19.3%
  2. TCRXLynx1 Capital Management LP filed Aug 14, 2026 Schedule 13G/A passive issuer: TScan Therapeutics, Inc. filing 13.1%
  3. CCCCLynx1 Capital Management LP filed Aug 14, 2026 Schedule 13G/A passive issuer: C4 Therapeutics, Inc. filing 9.99%
  4. STOKLynx1 Capital Management LP filed Aug 14, 2026 Schedule 13G/A passive issuer: Stoke Therapeutics, Inc. filing 6.5%
  5. IBIOLynx1 Capital Management LP filed Aug 14, 2026 Schedule 13G passive issuer: iBio, Inc. filing 5.4%
  6. DTILLynx1 Capital Management LP filed Jul 20, 2026 Schedule 13G passive issuer: PRECISION BIOSCIENCES INC filing 5.4%
  7. PASGLynx1 Capital Management LP filed Jul 2, 2026 Schedule 13D may seek influence 673,759 shares issuer: Passage BIO, Inc. filing 21%